[1]
|
国家癌症中心, 国家肿瘤质控中心前列腺癌质控专家委员会. 中国前列腺癌规范诊疗质量控制指标(2022版) [J]. 中华肿瘤杂志, 2022, 44(10): 1011-1016.
|
[2]
|
Siegel, D.A., O’neil, M.E., Richards, T.B., et al. (2020) Prostate Cancer Incidence and Survival, by Stage and Race/ Ethnicity—United States, 2001-2017. MMWR Morbidity and Mortality Weekly Report, 69, 1473-1480.
https://doi.org/10.15585/mmwr.mm6941a1
|
[3]
|
Rathkopf, D.E., Antonarakis, E.S., Shore, N.D., et al. (2017) Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research: An Official Journal of the American Asso-ciation for Cancer Research, 23, 3544-3551.
https://doi.org/10.1158/1078-0432.CCR-16-2509
|
[4]
|
Zhou, Y., Bolton, E.C. and Jones, J.O. (2015) Androgens and Androgen Receptor Signaling in Prostate Tumorigenesis. Journal of Molecular Endocrinology, 54, R15-R29. https://doi.org/10.1530/JME-14-0203
|
[5]
|
Logothetis, C.J. and Schellhammer, P.F. (2008) High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa), 1, 151-152. https://doi.org/10.1158/1940-6207.CAPR-08-0085
|
[6]
|
Deocampo, N.D., Huang, H. and Tindall, D.J. (2003) The Role of PTEN in the Progression and Survival of Prostate Cancer. Minerva Endocrinologica, 28, 145-153.
|
[7]
|
Abate-Shen, C., Banach-Petrosky, W.A., Sun, X., et al. (2003) Nkx3.1; Pten Mutant Mice Develop Inva-sive Prostate Adenocarcinoma and Lymph Node Metastases. Cancer Research, 63, 3886-3890.
|
[8]
|
Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., et al. (2003) Myc-Driven Murine Prostate Cancer Shares Molecular Features with Human Prostate Tumors. Cancer Cell, 4, 223-238. https://doi.org/10.1016/S1535-6108(03)00197-1
|
[9]
|
Aytes, A., Mitro-fanova, A., Lefebvre, C., et al. (2014) Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF That Drives Prostate Cancer Malignancy. Cancer Cell, 25, 638-651.
https://doi.org/10.1016/j.ccr.2014.03.017
|
[10]
|
Goldstein, A.S., Huang, J., Guo, C., et al. (2010) Identification of a Cell of Origin for Human Prostate Cancer. Science (New York, NY), 329, 568-571. https://doi.org/10.1126/science.1189992
|
[11]
|
Dulińska-Litewka, J., Felkle, D., Dykas, K., et al. (2022) The Role of Cyclins in the Development and Progression of Prostate Cancer. Biomedicine & Pharmacotherapy, 155, Article ID: 113742.
https://doi.org/10.1016/j.biopha.2022.113742
|
[12]
|
Tew, B.Y., Hong, T.B., Otto-Duessel, M., et al. (2017) Vitamin K Epoxide Reductase Regulation of Androgen Receptor Activity. Oncotarget, 8, 13818-13831. https://doi.org/10.18632/oncotarget.14639
|
[13]
|
Rosen, E.D. and Spiegelman, B.M. (2001) PPARgamma: A Nu-clear Regulator of Metabolism, Differentiation, and Cell Growth. The Journal of Biological Chemistry, 276, 37731-37734. https://doi.org/10.1074/jbc.R100034200
|
[14]
|
Muntean, C., Sasaran, M.O., Crisan, A., et al. (2022) Effects of PPARG and PPARGC1A Gene Polymorphisms on Obesity Markers. Frontiers in Public Health, 10, Article ID: 962852. https://doi.org/10.3389/fpubh.2022.962852
|
[15]
|
Skóra, B., Matuszewska, P., Masicz, M., et al. (2022) Crosstalk between the Aryl Hydrocarbon Receptor (AhR) and the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Key Factor in the Metabolism of Silver Nanoparticles in Neuroblastoma (SH-SY5Y) Cells in Vitro. Toxi-cology and Applied Pharmacology, 2022, Article ID: 116339.
https://doi.org/10.1016/j.taap.2022.116339
|
[16]
|
Hernandez-Quiles, M., Broekema, M.F. and Kalkhoven, E. (2021) PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Frontiers in Endocri-nology, 12, Article ID: 624112.
https://doi.org/10.3389/fendo.2021.624112
|
[17]
|
Rochel, N., Krucker, C., Coutos-Thévenot, L., et al. (2019) Re-current Activating Mutations of PPARγ Associated with Luminal Bladder Tumors. Nature Communications, 10, 253. https://doi.org/10.1038/s41467-018-08157-y
|
[18]
|
Forootan, F.S., Forootan, S.S., Malki, M.I., et al. (2014) The Expression of C-FABP and PPARγ and Their Prognostic Significance in Prostate Cancer. International Journal of On-cology, 44, 265-275. https://doi.org/10.3892/ijo.2013.2166
|
[19]
|
Rogenhofer, S., Ellinger, J., Kahl, P., et al. (2012) Enhanced Expression of Peroxisome Proliferate-Activated Receptor Gamma (PPAR-γ) in Advanced Prostate Cancer. An-tiCancer Research, 32, 3479-3483.
|
[20]
|
Park, H.K., Kim, H., Kim, H.G., et al. (2015) Expression of Peroxisome Pro-liferator Activated Receptor Gamma in Prostatic Adenocarcinoma. Journal of Korean Medical Science, 30, 533-541.
https://doi.org/10.3346/jkms.2015.30.5.533
|
[21]
|
祝海, 翁博文, 贾勇, 等. Id1介导曲格列酮抑制前列腺癌PC-3细胞侵袭分子机制探讨[C]//中国中西医结合学会泌尿外科专业委员会第十四次全国学术会议暨2016年广东省中西医结合学会泌尿外科专业委员会学术年会. 2016: 773.
|
[22]
|
Segawa, Y., Yoshimura, R., Hase, T., et al. (2002) Expression of Peroxisome Proliferator-Activated Receptor (PPAR) in Human Prostate Cancer. The Prostate, 51, 108-116. https://doi.org/10.1002/pros.10058
|
[23]
|
Dong, F.L., Liu, D.M., Lu, T.T., et al. (2022) PPARγ2 Func-tions as a Tumor Suppressor in a Translational Mouse Model of Human Prostate Cancer. Asian Journal of Andrology, 24, 90-96. https://doi.org/10.4103/aja.aja_51_21
|
[24]
|
Torrano, V., Valcarcel-Jimenez, L., Cortazar, A.R., et al. (2017) Erratum: The Metabolic Co-Regulator PGC1α Suppresses Prostate Cancer Metastasis. Nature Cell Biology, 19, 873. https://doi.org/10.1038/ncb3558
|
[25]
|
Fröhlich, E. and Wahl R. (2015) Chemotherapy and Chemoprevention by Thiazolidinediones. BioMed Research International, 2015, Article ID: 845340. https://doi.org/10.1155/2015/845340
|
[26]
|
Yang, C.C., Wang, Y.C., Wei, S., et al. (2007) Peroxisome Prolifera-tor-Activated Receptor Gamma-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation. Cancer Research, 67, 3229-3238. https://doi.org/10.1158/0008-5472.CAN-06-2759
|
[27]
|
Shiau, C.W., Yang, C.C., Kulp, S.K., et al. (2005) Thiazol-idenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Inde-pendently of PPARgamma. Cancer Research, 65, 1561-1569.
https://doi.org/10.1158/0008-5472.CAN-04-1677
|
[28]
|
Qin, L., Gong, C., Chen, A.M., et al. (2014) Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Inhibits Migration and Invasion of Prostate Cancer Cells through Inhibition of the CXCR4/CXCL12 Axis. Molecular Medicine Reports, 10, 695-700. https://doi.org/10.3892/mmr.2014.2232
|
[29]
|
Qin, L., Ren, Y., Chen, A.M., et al. (2014) Peroxisome Prolifera-tor-Activated Receptor γ Ligands Inhibit VEGF-Mediated Vasculogenic Mimicry of Prostate Cancer through the AKT Signaling Pathway. Molecular Medicine Reports, 10, 276- 282. https://doi.org/10.3892/mmr.2014.2198
|
[30]
|
Forootan, F.S., Forootan, S.S., Gou, X., et al. (2016) Fatty Acid Ac-tivated PPARγ Promotes Tumorigenicity of Prostate Cancer Cells by Up Regulating VEGF via PPAR Responsive Ele-ments of the Promoter. Oncotarget, 7, 9322-9339.
https://doi.org/10.18632/oncotarget.6975
|
[31]
|
Ahmad, I., Mui, E., Galbraith, L., et al. (2016) Sleeping Beauty Screen Reveals Pparg Activation in Metastatic Prostate Cancer. Proceedings of the National Academy of Sciences of the United States of America, 113, 8290-8295.
https://doi.org/10.1073/pnas.1601571113
|
[32]
|
Galbraith, L.C.A., Mui, E., Nixon, C., et al. (2021) PPAR-Gamma Induced AKT3 Expression Increases Levels of Mitochondrial Biogenesis Driving Prostate Cancer. Oncogene, 40, 2355-2366.
https://doi.org/10.1038/s41388-021-01707-7
|
[33]
|
温珊, 苏衍萍. PPARγ的抗肿瘤作用的研究进展[J]. 世界最新医学信息文摘, 2019, 19(63): 100-101.
|
[34]
|
朱绍兴, 陈流, 王彬. 吡格列酮诱导前列腺癌PC-3细胞凋亡的实验研究[J]. 福建医科大学学报, 2008(5): 404-407.
|
[35]
|
Chang, S.N., Lee, J.M., Oh, H., et al. (2018) Troglitazone Inhib-its the Migration and Invasion of PC-3 Human Prostate Cancer Cells by Upregulating E-Cadherin and Glutathione Pe-roxidase 3. Oncology Letters, 16, 5482-5488.
https://doi.org/10.3892/ol.2018.9278
|
[36]
|
Yoshimura, R., Matsuyama, M., Hase, T., et al. (2003) The Effect of Peroxisome Proliferator-Activated Receptor- Gamma Ligand on Urological Cancer Cells. International Journal of Mo-lecular Medicine, 12, 861-865.
https://doi.org/10.3892/ijmm.12.6.861
|
[37]
|
Chaffer, C.L., Thomas, D.M., Thompson, E.W., et al. (2006) PPAR-gamma-Independent Induction of Growth Arrest and Apoptosis in Prostate and Bladder Carcinoma. BMC Cancer, 6, 53. https://doi.org/10.1186/1471-2407-6-53
|
[38]
|
Suzuki, S., Mori, Y., Nagano, A., et al. (2016) Pioglitazone, a Perox-isome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. International Journal of Mo-lecular Sciences, 17, 2071.
https://doi.org/10.3390/ijms17122071
|
[39]
|
Uemura, H., Hoshino, K. and Kubota, Y. (2011) Role of Ren-in-Angiotensin System and Antitumor Effect of ARB in Prostate Cancer. Nihon Rinsho Japanese Journal of Clinical Medicine, 69, 155-159.
|
[40]
|
Woo, Y. and Jung, Y.J. (2017) Angiotensin II Receptor Blockers Induce Autophagy in Prostate Cancer Cells. Oncology Letters, 13, 3579-3585. https://doi.org/10.3892/ol.2017.5872
|